- Home
- MRLN vs OPK Comparison
MRLN vs OPK Comparison
Compare MRLN & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRLN | OPK |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 915.1M | 921.2M |
| IPO Year | 2024 | 2011 |
Fundamental Metrics
Financial Performance| Metric | MRLN | OPK |
|---|---|---|
| Price | $8.09 | $1.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $25.00 | $1.60 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 10-28-2021 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.78 | $0.98 |
| 52 Week High | $17.00 | $1.60 |
Technical Indicators
Market Signals| Indicator | MRLN | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 82.58 |
| Support Level | $6.07 | $1.25 |
| Resistance Level | $17.00 | $1.52 |
| Average True Range (ATR) | 0.85 | 0.06 |
| MACD | 0.19 | 0.03 |
| Stochastic Oscillator | 76.66 | 89.41 |
Price Performance
Historical ComparisonAbout MRLN Merlin Inc. Common Stock
Merlin Inc is focused on developing autonomous flight software for legacy and next-generation airborne systems. Its aircraft-agnostic, AI-based software supports takeoff-to-landing autonomous operations for military and civil aviation programs. The company aims to build an AI-based operating software platform intended to support autonomous flight operations across a range of aircraft types.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.